
CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome
Neurology® Podcast
00:00
A New Treatment for Alzheimer's Disease
The study has essentially established is that one can deliver a crisper casnine therapeutic at least safely, certainly in a short term. The real challenge over the next five, ten years is going to be delivery, delivery. And i think what we're going to need is the technology to deliver these crispacas, nine therapeutics to a wide range of cells if we want this to really revolutionize medicine.
Transcript
Play full episode